Abstract:Background & AimsLiver biopsy is the reference standard for staging and grading non-alcoholic fatty liver disease (NAFLD), but histologic scoring systems are semi-quantitative with marked inter- and intra-observer variation. We used machine learning to develop fully automated software for quantification of steatosis, inflammation, ballooning, and fibrosis in biopsies from patients with NAFLD and validated the technology in a separate group of patients.MethodsWe collected data from 246 consecutive patients with biopsy-proven NAFLD and followed in London, the United Kingdom, from January 2010 through December 2016. Biopsies from the first 100 patients were used to derive the algorithm and biopsies from the following 146 were used to validate it. Biopsies were independently scored by pathologists using the nonalcoholic steatohepatitis clinical research network criteria and digitalized. Areas of steatosis, inflammation, ballooning, and fibrosis were annotated on biopsies by 2 hepatobiliary histopathologists to facilitate machine learning. Images of biopsies from the derivation and validation sets were then analyzed by the algorithm to compute percentages of fat, inflammation, ballooning, and fibrosis, as well as collagen proportionate area (CPA), and compared with findings from pathologists' manual annotations and conventional scoring systems.ResultsIn the derivation group, results from manual annotation and the software had an inter-class correlation coefficient (ICC) of 0.97 for steatosis (95%CI, 0.95–0.99; P<.001); ICC, 0.96 for inflammation (95%CI, 0.9–0.98; P<.001); ICC, 0.94 for ballooning (95%CI, 0.87–0.98; P<.001); and ICC, 0.92 for fibrosis (95%CI, 0.88–0.96; P=.001). Percentages of fat, inflammation, ballooning, and CPA from the derivation group were confirmed in the validation cohort. The software identified histological features of NAFLD with levels of inter- and intra-observer agreement ranging from 0.95 to 0.99; this value was higher than that of semi-quantitative scoring systems which ranged 0.58 to 0.88. In a subgroup of paired liver biopsies, quantitative analysis was more sensitive in detecting differences compared to the nonalcoholic steatohepatitis Clinical Research Network scoring system.ConclusionsWe used machine learning to develop software to rapidly and objectively analyse liver biopsies for histologic features of NAFLD. The results from the software correlate with those from histopathologists, with high levels of inter- and intra-observer agreement. Findings were validated in a separate group of patients. This tool might be used for objective assessment of response to therapy for NAFLD in practice and clinical trials.

Machine learning models predict liver steatosis but not liver fibrosis in a prospective cohort study

Machine Learning Models for Predicting Significant Liver Fibrosis in Patients with Severe Obesity and Nonalcoholic Fatty Liver Disease

Implementation of Machine Learning Algorithms to Screen for Advanced Liver Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: An In-Depth Explanatory Analysis

Machine learning improves the prediction of significant fibrosis in Asian patients with metabolic dysfunction‐associated steatotic liver disease – The Gut and Obesity in Asia (GO‐ASIA) Study

Application of Machine Learning Techniques for Clinical Predictive Modeling: A Cross-Sectional Study on Nonalcoholic Fatty Liver Disease in China

Machine Learning to Predict Progression of Non‐alcoholic Fatty Liver to Non‐alcoholic Steatohepatitis or Fibrosis

Prediction of Fatty Liver Disease in a Chinese Population Using Machine-Learning Algorithms

Application of Interpretable Machine Learning Models Based on Ultrasonic Radiomics for Predicting the Risk of Fibrosis Progression in Diabetic Patients with Nonalcoholic Fatty Liver Disease

Machine-Learning Algorithm for Predicting Fatty Liver Disease in a Taiwanese Population

Machine learning-based mortality prediction models for non-alcoholic fatty liver disease in the general United States population

Application of machine learning in predicting non-alcoholic fatty liver disease using anthropometric and body composition indices

Machine learning algorithm outperforms fibrosis markers in predicting significant fibrosis in biopsy-confirmed NAFLD

Ultrasound‐Based Machine Learning Approach for Detection of Nonalcoholic Fatty Liver Disease

Development and validation of machine learning models for nonalcoholic fatty liver disease

Comparison of Machine Learning Models and the Fatty Liver Index in Predicting Lean Fatty Liver

A Machine Learning Model to Predict Risk for Hepatocellular Carcinoma in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease

Machine‐learning model comprising five clinical indices and liver stiffness measurement can accurately identify MASLD‐related liver fibrosis

An explainable machine learning model for prediction of high-risk nonalcoholic steatohepatitis

Machine Learning-Based Models for Advanced Fibrosis and Cirrhosis Diagnosis in Chronic Hepatitis B Patients With Hepatic Steatosis

Comparison and development of advanced machine learning tools to predict nonalcoholic fatty liver disease: An extended study

High-Throughput, Machine Learning–Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease